DexCom, Inc. - Common Stock (DXCM)
85.76
+0.90 (1.05%)
NASDAQ · Last Trade: May 30th, 2:16 PM EDT

While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Via StockStory · May 30, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill · May 28, 2025

Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · May 28, 2025
Via The Motley Fool · May 27, 2025
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Via StockStory · May 26, 2025
Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Via StockStory · May 20, 2025
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Via Benzinga · May 19, 2025
Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.
Via StockStory · May 15, 2025
The company's bookings grew more than 20% for the second straight quarter, and the book-to-bill ratio exceeded one.
Via Stocktwits · May 14, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 13%. This drawdown was worse than the S&P 500’s 5.5% decline.
Via StockStory · May 12, 2025
Dexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market.
Via MarketBeat · May 8, 2025
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · May 6, 2025
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.
Via Benzinga · May 4, 2025
U.S. stocks rose on hopes of China's willingness to negotiate a trade deal regarding fentanyl production. Tech stocks led the rally.
Via Benzinga · May 2, 2025
U.S. stocks advanced across the board by midday Friday, with the S&P 500 eyeing its ninth consecutive day of gains—poised for the longest winning streak since May 2024.
Via Benzinga · May 2, 2025
Via Benzinga · May 2, 2025
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.32 per share was in line with analysts’ consensus estimates.
Via StockStory · May 1, 2025
Medical device company DexCom (NASDAQ:DXCM)
will be reporting results tomorrow after market hours. Here’s what to look for.
Via StockStory · April 30, 2025
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced trade tariffs on April 2.
Via Benzinga · May 1, 2025
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.
Via Talk Markets · April 24, 2025